Agency IQ

JANUARY 26, 2024

To support industry’s accurate identification and updating of drug expiration dates, the FDA has released a handful of guidance documents for industry. Such a situation is commonplace in the clinical trial realm, in which investigational drug products which are not already FDA approved are administered to patients.

Science 40

Science FDA Production Packaging 40

Agency IQ

NOVEMBER 10, 2023

. | NOV 8, 2023 10:02 PM CST Regulatory background The Federal Food, Drug, and Cosmetics Act (FD&C Act) is administered by the Food and Drug Administration (FDA) and regulates cosmetics. MoCRA also requires all marketed cosmetic products to be listed with the FDA by December 29, 2023.

Production 40

Production FDA Compliance Packaging 40

Agency IQ

JUNE 2, 2023

Within the realm of FDA-required labeling, there are currently a few different types of information a sponsor might develop specifically for patient use: medication guides, instructions for use (IFU), consumer medical information (CMI) and patient package inserts (PPI). The format of the PMI : At just one page (8.5×11

FDA 40

FDA FDA Approval Production Regulations 40

FDA Law Blog: Biosimilars

SEPTEMBER 30, 2024

The term “drug product information” is now defined to include NDC, drug name, units per package size (UPPS), drug category (S, I, or N), unit type (e.g., Remarkably, manufacturers may not dispute a CMS notification.

Drugs 59

Drugs Regulations International Production 59

The Pharma Data

AUGUST 6, 2020

See “Worldwide Pro Forma Revenue” in Quarterly Package of Financial Information for this quarter, which is available on bms.com/investors/financial-reporting/quarterly-results, for information on the revenue of the company and Celgene on a stand-alone basis for the prior-year period. Oncology and Hematology. Regulatory. Regulatory.

Production 52

Production International Licensing Licensing 52

Agency IQ

NOVEMBER 3, 2023

The prebiotic may either feed the probiotic that it is packaged with, or it may feed another beneficial microbe that is intended to complement the activity of the probiotic. In fact, the FDA has even developed a guidance document for “early clinical trials with live biotherapeutic products [LBPs].”

Therapies 40

Therapies Science FDA Production 40

The Pharma Data

DECEMBER 17, 2020

These follow-on data provided the first definitive prospective evidence demonstrating anti-viral activity for a treatment regimen now available for COVID-19, and also further documented the ability of this treatment to decrease the need for further medical attention,” said George D. Yancopoulos , M.D.,

Hospitals 52

Hospitals Production Clinical Trials Therapies 52

Agency IQ

JULY 8, 2024

Still, three years later, the FDA reported that it had received several reports of medical gas mix-ups resulting in at least 8 patient deaths and 16 serious patient injuries between 1996 and April 2004. It also proposed several packaging changes to safeguard against misidentification. The Medical Gas Safety Act , introduced by Rep.

FDA 40

FDA Regulations Production Packaging 40

Agency IQ

JANUARY 19, 2024

The FDA CRL cited inspection findings that arose from a “multi-sponsor inspection of a third-party, contract manufacturing organization” which involved the monoclonal antibody drug substance for lebrikizumab. The clinical package, safety and label were not affected. However, BeiGene announced that it is seeking approval in the U.S.

Biosimilars 40

Biosimilars FDA Production Treatment 40

Agency IQ

OCTOBER 27, 2023

What we expect to be talking about in November and December: Diversity Action Plan guidance : There is perhaps no guidance that FDA is working on that is as hotly anticipated as its Diversity Action Plan (DAP) guidance, which is set for release anytime between now and December 29. Government shutdown: At present, the U.S.

FDA 40

FDA Science Regulations Production 40

Agency IQ

MAY 31, 2024

sensitivity and specificity) – including colonoscopy procedures and an FDA-approved stool-based test ( Cologuard ) – but comparatively low uptake, given the prevalence of CRC in the population. Notably, CRC screening methods are currently available and have generally high performance (i.e.,

FDA 40

FDA Laboratories Compliance Packaging 40

Agency IQ

JUNE 16, 2023

The 51 regulations that FDA is currently working on The FDA today unveiled its much-anticipated Spring 2023 Unified Agenda, a document outlining the regulations the agency plans to release in 2023 and beyond. FDA has proposed to amend the 503A Bulks List by placing additional bulk drug substances on the list.

Regulations 40

Regulations FDA Science Production 40

Agency IQ

DECEMBER 1, 2023

What we expect to be talking about in December and January: Diversity Action Plan guidance : There is perhaps no guidance that FDA is working on that is as hotly anticipated as its Diversity Action Plan (DAP) guidance, which is set for release anytime between now and December 29. This is what OIRA is currently reviewing.

FDA 40

FDA Science Regulations Production 40

Agency IQ

MARCH 7, 2024

BY LAURA DIANGELO, MPH | MAR 6, 2024 5:54 PM CST Fiscal year 2024 appropriations bills On March 3, 2024, House and Senate appropriators released a package of final fiscal year (FY) 2024 appropriations bills. The budget agreement “asks” the FDA for some information and activities, and “recognizes” some FDA authority in other areas.

FDA 40

FDA Packaging Science Drugs 40

Agency IQ

JANUARY 12, 2024

After lengthy review, FDA approves Florida’s drug importation plan After a years-long review process, the FDA today announced its approval of Florida’s proposal to import certain prescription drug products from Canada. Drug labeling : Labeling for the imported drug product must be consistent with the current required U.S.

FDA Approval 40

FDA Approval FDA Science Drugs 40

The Pharma Data

MAY 5, 2021

FDA approves 100th monoclonal antibody product ( Nature Reviews Drug Discovery ). AI, digital health feature in latest batch of FDA breakthrough device designations ( MedTech Dive ). BD Taps Contract Packager for COVID-19 Test Kits ( MD+DI ). Medtech.

Vaccine 52

Vaccine FDA FDA Approval International 52

Drug & Device Law

DECEMBER 29, 2023

The FDA requires real science for warnings; thus it had not mandated any warning remotely resembling Prop 65. The plaintiff failed to identify any method by which a generic (or any other) drug manufacturer could add a Prop 65 warning without deviating from FDA-approved labeling, thereby violating federal law. See 2023 Mich.

Testimonials 105

Testimonials FDA Drugs Vaccine 105

Drug & Device Law

SEPTEMBER 12, 2022

Both propositions are well recognized, but Pfaff ties them together in one neat package. The FDA decided against it, but “did not also inform the [defendant].” When the FDA approved [defendant’s] supplemental CBE in 2011, [defendant] was not aware of the impossibility of adding a suicidality warning under federal law.

FDA 59

FDA FDA Approval Regulations International 59